AI assistant
Innoviva, Inc. — Director's Dealing 2014
Feb 20, 2014
32090_dirs_2014-02-19_7be426fb-382f-42f6-bc79-5048e3b92be5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: THERAVANCE INC (THRX)
CIK: 0001080014
Period of Report: 2014-02-14
Reporting Person: Mammen Mathai (SVP, Research & Early Clin Dev)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-02-14 | Common Stock | S | 30400 | $39.26 | Disposed | 191223 | Direct |
| 2014-02-14 | Common Stock | S | 4600 | $40.04 | Disposed | 186623 | Direct |
Footnotes
F1: DISPOSITIONS MADE PURSUANT TO A PLAN INTENDED TO COMPLY WITH RULE 10b5-1(c).
F2: This transaction was executed in multiple trades at prices ranging from $38.78 to $39.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $39.80 to $40.38. The price reported above reflects the weighted average sale price.